{"id":1263,"date":"2020-09-16T06:58:00","date_gmt":"2020-09-16T06:58:00","guid":{"rendered":"https:\/\/aceoncology.org\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers"},"modified":"2021-03-05T05:07:25","modified_gmt":"2021-03-05T05:07:25","slug":"selpercatinib-a-new-treatment-option-for-ret-altered-cancers","status":"publish","type":"post","link":"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/","title":{"rendered":"Selpercatinib, a New Treatment Option for RET-Altered Cancers"},"content":{"rendered":"\n<p>Alterations in the <em>RET<\/em> gene are involved in the pathogenesis of around 2% of cancers. The common alterations that lead to <em>RET <\/em>tyrosine kinase activation are mutations (around 37%) and gene fusions (around 31%). <em>RET <\/em>mutations have been found in most patients with sporadic medullary thyroid carcinoma (MTC) and are commonly associated with multiple endocrine neoplasia (MEN) and familial MTC. <em>RET <\/em>fusions are oncogenic drivers in a variety of cancers, including 10 \u2013 20% of papillary thyroid cancers, 1 \u2013 2% of non-small cell lung cancers (NSCLC), and in small subgroups of colorectal, breast and other cancers. Until recently, only multikinase inhibitors with non-selective RET inhibitory activity (vandetanib and cabozantinib) have been available for select patients with <em>RET<\/em>-altered cancers. However, the efficacy of these agents is modest, and their use is limited because of their off-target side effects. Conversely, next generation RET inhibitors such as selpercatinib and pralsetinib have been found to be highly potent and selective for RET with favorable toxicity profile.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>The efficacy and safety of selpercatinib in patients with solid tumors harboring an activating <em>RET <\/em>alteration is evaluated in an international, open-label, phase I\/II LIBRETTO-001 trial. Preliminary data from 162 patients with <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2005651\" rel=\"noreferrer noopener\" target=\"_blank\">thyroid cancer<\/a>, and 144 patients with <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2005653\" rel=\"noreferrer noopener\" target=\"_blank\">NSCLC<\/a>, were recently reported in the <em>New England Journal of Medicine.<\/em> The primary endpoint of the trial is objective response rate (ORR) per independent review committee; secondary endpoints include duration of response (DOR), progression-free survival (PFS), and safety. In patients with <strong><em>RET-mutant MTC<\/em><\/strong>, who had previously received vandetanib and\/or cabozantinib, the ORR was 69% and 1-year PFS was 82%; among treatment-naive patients, the ORR was 73% and 1-year PFS was 92%. In patients who had previously treated <strong><em>RET fusion-positive thyroid cancer<\/em><\/strong>, the ORR was 79% and 1-year PFS was 64%. Patients with <strong><em>RET fusion-positive NSCLC<\/em><\/strong> who had previously received at least platinum-based chemotherapy had an ORR of 64% and DOR was 17.5 months; the 1-year PFS was 66% with a median PFS of 16.5 months. Furthermore, among previously treated patients who had measurable central nervous system (CNS) metastasis at enrolment, the objective intracranial response rate was 91%. In treatment-naive patients with <em>RET <\/em>fusion-positive NSCLC, the ORR was 85%, and 90% of the responses were ongoing at 6 months; neither median DOR nor median PFS had been reached at a median follow-up of 7.4 months and 9.2 months, respectively. The adverse events profile of selpercatinib was broadly similar across all patients, the most common grade 3\/4 adverse events were hypertension, increased level of aminotransferases, hyponatremia and lymphopenia. Discontinuation of selpercatinib due to drug-related adverse events occurred in 12% of patients with thyroid cancer and 2% of patients with NSCLC.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Data from the LIBRETTO-001 trial demonstrate that selpercatinib has durable efficacy and mainly low-grade toxicity in patients with <em>RET-<\/em>mutant MTC, and <em>RET <\/em>fusion-positive thyroid cancer and NSCLC, including those with CNS metastasis. Detecting <em>RET <\/em>alterations is therefore vital for identifying patients who may benefit from selpercatinib treatment. Based on these impressive results, the US Food and Drug Administration (FDA) approved selpercatinib for the treatment of <em>RET-<\/em>altered thyroid cancer and NSCLC (see details in <a href=\"https:\/\/aceoncology.org\/#aceoncoblog\/FDA-approvals-May-2020\" rel=\"noreferrer noopener\" target=\"_blank\">ACE OncoBlog 12 June 2020<\/a>). In an <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMe2024831\" rel=\"noreferrer noopener\" target=\"_blank\">editorial<\/a> accompanying the LIBRETTO-001 trial results, Dr. Razelle Kurzrock (<em>Moores Cancer Center, University of California, San Diego, USA<\/em>) concluded that \u201c<em>RET<\/em> abnormalities now join other genomic alterations such as <em>NTRK<\/em> fusions, tumor mutational burden, and deficient mismatch repair genes across cancers and <em>ALK<\/em>,<em> BRAF<\/em>,<em> EGFR<\/em>,<em> MET<\/em>, and<em> ROS1<\/em> alterations in NSCLC that warrant molecular screening strategies\u201d.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong>References<\/strong><\/p>\n\n\n\n<p>Wirth LJ, et al. <em>N Engl J Med.<\/em>2020;383:825-35.<\/p>\n\n\n\n<p>Drilon A, et al. <em>N Engl J Med. <\/em>2020;383:813-24.<\/p>\n\n\n\n<p>Kurzrock R. <em>N Engl J Med<\/em>. 2020;383:868-869.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alterations in the RET gene are involved in the pathoge [&hellip;]<\/p>\n","protected":false},"author":434,"featured_media":696,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-1263","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Selpercatinib, a New Treatment Option for RET-Altered Cancers - ACE Oncology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Selpercatinib, a New Treatment Option for RET-Altered Cancers - ACE Oncology\" \/>\n<meta property=\"og:description\" content=\"Alterations in the RET gene are involved in the pathoge [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/\" \/>\n<meta property=\"og:site_name\" content=\"ACE Oncology\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-16T06:58:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-05T05:07:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/09\/file-1600084661443-Blog-Post-Picture21_Selpercatinib.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1250\" \/>\n\t<meta property=\"og:image:height\" content=\"834\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pascha Paularin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:site\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pascha Paularin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/\"},\"author\":{\"name\":\"Pascha Paularin\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/d8f6edf15a20f14b3b57d44c6be51e33\"},\"headline\":\"Selpercatinib, a New Treatment Option for RET-Altered Cancers\",\"datePublished\":\"2020-09-16T06:58:00+00:00\",\"dateModified\":\"2021-03-05T05:07:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/\"},\"wordCount\":579,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/09\/file-1600084661443-Blog-Post-Picture21_Selpercatinib.jpg\",\"articleSection\":[\"\u6587\u7ae0\u7cbe\u8981\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/\",\"url\":\"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/\",\"name\":\"Selpercatinib, a New Treatment Option for RET-Altered Cancers - ACE Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/09\/file-1600084661443-Blog-Post-Picture21_Selpercatinib.jpg\",\"datePublished\":\"2020-09-16T06:58:00+00:00\",\"dateModified\":\"2021-03-05T05:07:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/#primaryimage\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/09\/file-1600084661443-Blog-Post-Picture21_Selpercatinib.jpg\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/09\/file-1600084661443-Blog-Post-Picture21_Selpercatinib.jpg\",\"width\":1250,\"height\":834,\"caption\":\"ACE-Oncoblog-21-Selpercatinib\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"ACE Oncology\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Selpercatinib, a New Treatment Option for RET-Altered Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/aceoncology.org\/#website\",\"url\":\"https:\/\/aceoncology.org\/\",\"name\":\"ACE Oncology\",\"description\":\"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.\",\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/aceoncology.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/aceoncology.org\/#organization\",\"name\":\"ACE Oncology\",\"url\":\"https:\/\/aceoncology.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"width\":156,\"height\":83,\"caption\":\"ACE Oncology\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ace_oncology\",\"https:\/\/www.linkedin.com\/company\/aceoncology\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/d8f6edf15a20f14b3b57d44c6be51e33\",\"name\":\"Pascha Paularin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/521645f985d3ddd8a50c2df03ffbf2a2554ac92274f36d665fac216d09fdf1d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/521645f985d3ddd8a50c2df03ffbf2a2554ac92274f36d665fac216d09fdf1d8?s=96&d=mm&r=g\",\"caption\":\"Pascha Paularin\"},\"url\":\"https:\/\/aceoncology.org\/zh-hans\/author\/ppaschaaceoncology-org\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Selpercatinib, a New Treatment Option for RET-Altered Cancers - ACE Oncology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/","og_locale":"zh_CN","og_type":"article","og_title":"Selpercatinib, a New Treatment Option for RET-Altered Cancers - ACE Oncology","og_description":"Alterations in the RET gene are involved in the pathoge [&hellip;]","og_url":"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/","og_site_name":"ACE Oncology","article_published_time":"2020-09-16T06:58:00+00:00","article_modified_time":"2021-03-05T05:07:25+00:00","og_image":[{"width":1250,"height":834,"url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/09\/file-1600084661443-Blog-Post-Picture21_Selpercatinib.jpg","type":"image\/jpeg"}],"author":"Pascha Paularin","twitter_card":"summary_large_image","twitter_creator":"@ace_oncology","twitter_site":"@ace_oncology","twitter_misc":{"\u4f5c\u8005":"Pascha Paularin","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"3 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/#article","isPartOf":{"@id":"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/"},"author":{"name":"Pascha Paularin","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/d8f6edf15a20f14b3b57d44c6be51e33"},"headline":"Selpercatinib, a New Treatment Option for RET-Altered Cancers","datePublished":"2020-09-16T06:58:00+00:00","dateModified":"2021-03-05T05:07:25+00:00","mainEntityOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/"},"wordCount":579,"commentCount":0,"publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/09\/file-1600084661443-Blog-Post-Picture21_Selpercatinib.jpg","articleSection":["\u6587\u7ae0\u7cbe\u8981"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/","url":"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/","name":"Selpercatinib, a New Treatment Option for RET-Altered Cancers - ACE Oncology","isPartOf":{"@id":"https:\/\/aceoncology.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/#primaryimage"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/09\/file-1600084661443-Blog-Post-Picture21_Selpercatinib.jpg","datePublished":"2020-09-16T06:58:00+00:00","dateModified":"2021-03-05T05:07:25+00:00","breadcrumb":{"@id":"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/#primaryimage","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/09\/file-1600084661443-Blog-Post-Picture21_Selpercatinib.jpg","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/09\/file-1600084661443-Blog-Post-Picture21_Selpercatinib.jpg","width":1250,"height":834,"caption":"ACE-Oncoblog-21-Selpercatinib"},{"@type":"BreadcrumbList","@id":"https:\/\/aceoncology.org\/zh-hans\/selpercatinib-a-new-treatment-option-for-ret-altered-cancers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"ACE Oncology","item":"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/"},{"@type":"ListItem","position":2,"name":"Selpercatinib, a New Treatment Option for RET-Altered Cancers"}]},{"@type":"WebSite","@id":"https:\/\/aceoncology.org\/#website","url":"https:\/\/aceoncology.org\/","name":"ACE Oncology","description":"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.","publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aceoncology.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/aceoncology.org\/#organization","name":"ACE Oncology","url":"https:\/\/aceoncology.org\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","width":156,"height":83,"caption":"ACE Oncology"},"image":{"@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ace_oncology","https:\/\/www.linkedin.com\/company\/aceoncology"]},{"@type":"Person","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/d8f6edf15a20f14b3b57d44c6be51e33","name":"Pascha Paularin","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/521645f985d3ddd8a50c2df03ffbf2a2554ac92274f36d665fac216d09fdf1d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/521645f985d3ddd8a50c2df03ffbf2a2554ac92274f36d665fac216d09fdf1d8?s=96&d=mm&r=g","caption":"Pascha Paularin"},"url":"https:\/\/aceoncology.org\/zh-hans\/author\/ppaschaaceoncology-org\/"}]}},"_links":{"self":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/1263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/users\/434"}],"replies":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/comments?post=1263"}],"version-history":[{"count":1,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/1263\/revisions"}],"predecessor-version":[{"id":1264,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/1263\/revisions\/1264"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media\/696"}],"wp:attachment":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media?parent=1263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/categories?post=1263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/tags?post=1263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}